We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Genetic Link to Premenopausal Breast Cancer Discovered

By LabMedica International staff writers
Posted on 03 Jul 2019
Breast cancer is the most common cancer in women, with an estimated one out of every eight women expected to develop it in their lifetimes. More...
While environmental factors like smoking, diet or lack of physical activity can lead to cancer, a person's genes also contribute to the risk of getting the disease.

Scientists have added a new genetic marker to the breast cancer map, helping to expand the list of genetic mutations clinicians can watch for in cancer screenings. Caucasian women carrying the genetic variation compared to women without the variation and in premenopausal women that risk reached as high as 40%. The ability to identify those genes and their variants (called alleles) can be vital to early detection and life-saving treatment.

Medical scientists at the University of Alberta (Edmonton, AB, Canada) examined breast cancer risk in Caucasian women divided into premenopausal and postmenopausal groupings. Because the majority of breast cancers are diagnosed in women over the age of 55, most genetic association studies focus on postmenopausal women. However, inherited forms of cancers, typically related to genetic mutations, are more likely to be more aggressive and be diagnosed earlier in life.

The team examined more than 9,000 women from Alberta for the study, utilizing samples from patients diagnosed with breast cancer and unaffected healthy controls. Genomic DNA was extracted from buffy coat samples using a commercially available Qiagen Tm kit. Genotyping was performed using Sequenom iPLEX Gold platform. Whole genome genotype data was generated using Human Affymetrix SNP 6.0 array (906,600 SNPs) for 348 cases and 348 controls.

The scientists reported that the SNP rs1429142 (C/T, minor allele frequency 18%) showed statistically significant association for the overall breast cancer risk in Stages 1–4 (n = 4,331 cases/4,271 controls), and an elevated risk among premenopausal women (n = 1,503 cases/4,271 controls) in European populations. SNP rs1429142 was associated with premenopausal breast cancer risk in women of African, but not from Chinese ancestry. Fine‐mapping of the locus revealed several potential causal variants, which are present within a single association signal, revealed from the conditional regression analysis.

The authors concluded that they had identified three potential causal variants (rs1366691, rs1429139 and rs7667633) strongly associated with premenopausal breast cancer risk and the variants appear to have enhancer functions, likely regulating the nearby target genes. The study was originally published online on May 14, 2019, in the International Journal of Cancer.

Related Links:
University of Alberta


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Automatic CLIA Analyzer
Shine i6000
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.